You are here: Industry Insights > trial

News List

Rejenevie™ Therapeutics Announces Start of AR-100 Trial americanpharmaceuticalreview
May 30, 2019
Rejenevie™ Therapeutics announced the commencement of the company's Phase II clinical trial to study the safety and effectiveness of its proprietary AR-100 immune restoration therapy to boost the function of the aging immune system.
Pfizer announces top-line results from Phase 3 Trial of LYRICA® (pregabalin) in primary generalized tonic-clonic seizures worldpharmanews
May 29, 2019
Pfizer Inc. (NYSE: PFE) announced today that a Phase 3 study to assess the use of LYRICA® (pregabalin) as adjunctive therapy for epilepsy patients 5 to 65 years of age with primary generalized tonic-clonic (PGTC) seizures did not meet its primary endpoint
First Patient Dosed in Trial of OncoSec's TAVO™, Epacadostat and KEYTRUDA® Combo americanpharmaceuticalreview
May 24, 2019
OncoSec announced that the first patient has been dosed in TRIFECTA, a triple combination clinical trial of OncoSec's TAVO™, an IDO1 drug (epacadostat) and KEYTRUDA® in patients with unresectable squamous cell carcinoma head and neck (SCCHN) cancer.
Mirikizimab moved to Phase III after positive trial findings europeanpharmaceuticalreview
May 24, 2019
Eli Lilly presents new data for their mirikizimab treatment for Crohn’s disease.
ImmunoGen shares plummet by 32% after FDA recommends new Phase 3 trial pharmafile
May 17, 2019
Shares in ImmunoGen fell 32% in premarket trading after the firm said the FDA had recommended a new Phase 3 trial of its ovarian cancer drug mirvetuximab soravtansine.
Clinical trial will test long acting HIV injection pharmafile
May 15, 2019
A long-acting, injectable HIV drug combo is to be tested in a clinical trial of 350 volunteers with HIV.
Provention Bio Announces Top-Line Results from its PRV-300 Trial americanpharmaceuticalreview
May 10, 2019
Provention Bio Announces Top-Line Results from its PRV-300 Trial.
AZ’ Calquence trial to stop early after hitting endpoints pharmatimes
May 09, 2019
AZ’ Calquence trial to stop early after hitting endpoints.
RedHill Biopharma enrols last patient in Phase II irritable bowel syndrome trial europeanpharmaceuticalreview
May 07, 2019
RedHill Biopharma has enrolled the last patient in the Phase II study with Bekinda for the treatment of diarrhoea-predominant irritable bowel syndrome…
SIRT is better tolerated than sorafenib, but doesn’t increase overall survival in HCC europeanpharmaceuticalreview
May 07, 2019
Results of the SARAH trial demonstrate that SIRT resulted in median overall survival (OS) of 8.0 months compared to 9.9 months with sorafenib (p=0.179)…

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page